Molecular Profiling in Cholangiocarcinoma: Translating Genomics into Clinical Impact

Cholangiocarcinoma has quietly become one of the clearest proof points that precision oncology can change outcomes—not just theory, but real patients, real time. This talk will show how molecular profiling is reshaping how we diagnose, stratify, and treat this disease. From FGFR2 fusions and IDH1 mutations to emerging targets and mechanisms of resistance, we’ll walk through how genomic insights are translated into meaningful clinical decisions at the bedside. Additionally, we’ll explore what comes next—how to think about timing of testing, integrating liquid biopsy, anticipating resistance, designing smarter trials, and collaborating as a community. The goal is to reframe cholangiocarcinoma not as a rare, intractable cancer, but as a model for what precision oncology can actually deliver when done well.